Dynamic Advisor Solutions LLC lifted its position in shares of Bristol-Myers Squibb (NYSE:BMY – Get Rating) by 18.7% in the first quarter, HoldingsChannel reports. The institutional investor owned 21,179 shares of the biopharmaceutical company’s stock after purchasing an additional 3,336 shares during the period. Dynamic Advisor Solutions LLC’s holdings in Bristol-Myers Squibb were worth $1,547,000 at the end of the most recent quarter.
Other hedge funds have also recently added to or reduced their stakes in the company. EagleClaw Capital Managment LLC increased its holdings in Bristol-Myers Squibb by 2.9% in the 3rd quarter. EagleClaw Capital Managment LLC now owns 64,447 shares of the biopharmaceutical company’s stock valued at $3,823,000 after purchasing an additional 1,800 shares in the last quarter. Dark Forest Capital Management LP acquired a new stake in Bristol-Myers Squibb in the 3rd quarter valued at $75,000. Thrivent Financial for Lutherans increased its holdings in Bristol-Myers Squibb by 5.7% in the 3rd quarter. Thrivent Financial for Lutherans now owns 148,241 shares of the biopharmaceutical company’s stock valued at $8,868,000 after purchasing an additional 7,928 shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in Bristol-Myers Squibb in the 3rd quarter valued at $63,000. Finally, Atria Investments LLC increased its holdings in Bristol-Myers Squibb by 3.1% in the 3rd quarter. Atria Investments LLC now owns 95,613 shares of the biopharmaceutical company’s stock valued at $5,657,000 after purchasing an additional 2,914 shares in the last quarter. Institutional investors and hedge funds own 73.07% of the company’s stock.
In other Bristol-Myers Squibb news, CEO Giovanni Caforio sold 30,000 shares of the firm’s stock in a transaction dated Monday, June 13th. The shares were sold at an average price of $74.04, for a total value of $2,221,200.00. Following the transaction, the chief executive officer now owns 551,104 shares of the company’s stock, valued at $40,803,740.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Sandra Leung sold 65,000 shares of the firm’s stock in a transaction dated Monday, June 6th. The stock was sold at an average price of $74.89, for a total transaction of $4,867,850.00. Following the completion of the transaction, the executive vice president now directly owns 308,627 shares in the company, valued at approximately $23,113,076.03. The disclosure for this sale can be found here. Company insiders own 0.09% of the company’s stock.
Shares of BMY stock opened at $76.55 on Thursday. The company has a debt-to-equity ratio of 1.18, a quick ratio of 1.23 and a current ratio of 1.32. Bristol-Myers Squibb has a one year low of $53.22 and a one year high of $78.61. The company’s 50-day simple moving average is $75.93 and its 200-day simple moving average is $69.82. The stock has a market capitalization of $162.98 billion, a price-to-earnings ratio of 27.15, a PEG ratio of 1.62 and a beta of 0.49.
Bristol-Myers Squibb (NYSE:BMY – Get Rating) last issued its earnings results on Friday, April 29th. The biopharmaceutical company reported $1.96 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.92 by $0.04. Bristol-Myers Squibb had a net margin of 13.31% and a return on equity of 48.37%. The firm had revenue of $11.65 billion for the quarter, compared to analysts’ expectations of $11.34 billion. During the same quarter last year, the company posted $1.74 earnings per share. Bristol-Myers Squibb’s revenue was up 5.2% on a year-over-year basis. As a group, research analysts forecast that Bristol-Myers Squibb will post 7.56 EPS for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Monday, August 1st. Shareholders of record on Friday, July 1st will be issued a $0.54 dividend. The ex-dividend date is Thursday, June 30th. This represents a $2.16 dividend on an annualized basis and a yield of 2.82%. Bristol-Myers Squibb’s dividend payout ratio is currently 76.60%.
About Bristol-Myers Squibb (Get Rating)
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis.
- Get a free copy of the StockNews.com research report on Bristol-Myers Squibb (BMY)
- Victoria’s Secret Stock is Out of the Box
- Downturn Gives These 3 Buys Juicy Dividend Yields
- Time For a Ride in Six Flags Stock
- Why Dollar General (NYSE: DG) Should Be In Your Portfolio
- Korn Ferry Is A Good Buy For The Recession And Beyond
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.